C21 Investments (CXXI) AI Stock Analysis

• Market Cap: C$91.58M
• Dividend Yield: N/A
• Average Volume (3M): 41.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: 23.29%
• EPS Growth: 33.65%
• Country: CA
• Employees: 114
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 118,040,070
• 10 Day Avg. Volume: 50,757
• 30 Day Avg. Volume: 41,578
• PEG Ratio: 1.66
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 1.37
• P/FCF Ratio: 34.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: C$0.42 ▼(-3.64% Downside)
• Action: Reiterated Date: 04/14/26
• Date: Action: Reiterated 04/14/26

The score is driven primarily by improving financial trajectory (strong TTM revenue growth and better operating margins with manageable leverage), but it is held back by continued net losses and uneven cash-flow durability. Technicals are mixed-to-weak, and valuation is constrained by a negative P/E and no dividend support.

Positive Factors

Vertical integration & dual channels

C21’s integrated model—cultivation, processing and sales via company-owned dispensaries plus wholesale—lets it capture margins across the value chain, control supply and product mix, and reduce reliance on third-party suppliers. This structural setup supports margin preservation and product differentiation over months.

Negative Factors

Persistent net losses and negative ROE

Despite operating improvement, the company remains unprofitable at the bottom line with negative ROE, indicating retained losses and limited shareholder return. Ongoing net losses constrain retained capital, reduce reinvestment capacity, and increase dependence on external financing if profitability does not convert to sustained net income.

C21 Investments Business Overview & Revenue Model

Company Description

C21 Investments (CXXI) is a diversified investment company focused on the cannabis sector, particularly in the cultivation, processing, and retail of cannabis products. The company operates in various states where cannabis is legal, providing a wi...

Read more

C21 Investments (CXXI) is a diversified investment company focused on the cannabis sector, particularly in the cultivation, processing, and retail of cannabis products. The company operates in various states where cannabis is legal, providing a wi...

How the Company Makes Money

C21 Investments makes money primarily by selling cannabis and cannabis-derived products through two main channels: (1) retail sales at company-owned dispensaries, where revenue is generated from direct-to-consumer transactions and the company capt...

Read more

C21 Investments makes money primarily by selling cannabis and cannabis-derived products through two main channels: (1) retail sales at company-owned dispensaries, where revenue is generated from direct-to-consumer transactions and the company capt...

C21 Investments Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Apr 2023	Apr 2022	Apr 2020
Income Statement
Total Revenue	33.27M	30.12M	28.29M	32.98M	37.70M
Gross Profit	13.99M	12.56M	11.15M	18.81M	13.32M
EBITDA	4.57M	2.90M	2.63M	20.72M	-19.56M
Net Income	-3.44M	-3.97M	-3.31M	9.96M	-32.56M
Balance Sheet
Total Assets	54.89M	57.00M	54.53M	61.85M	61.45M
Cash, Cash Equivalents and Short-Term Investments	2.42M	2.63M	2.41M	3.07M	3.08M
Total Debt	10.95M	13.15M	10.72M	18.67M	36.07M
Total Liabilities	28.05M	28.32M	23.48M	26.87M	47.87M
Stockholders Equity	26.84M	28.68M	31.05M	34.98M	13.58M
Cash Flow
Free Cash Flow	1.31M	-2.63M	5.46M	4.27M	5.00M
Operating Cash Flow	1.44M	1.19M	5.90M	6.84M	5.51M
Investing Cash Flow	223.14K	-3.12M	-390.93K	-1.39M	-4.54M
Financing Cash Flow	-1.78M	1.27M	-6.68M	-7.84M	-7.10M

C21 Investments Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CXXI, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.40, and above the 200-day MA of 0.43, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 62.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CXXI.

C21 Investments Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLY	67 Neutral	C$168.38M	4.61	27.19%	―	27.38%	―
CWEB	54 Neutral	C$134.13M	-1.92	-275.39%	―	-4.23%	37.33%
CXXI	52 Neutral	C$91.58M	-18.63	-12.42%	―	23.29%	33.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JUSH	49 Neutral	C$143.78M	-2.48	75.97%	―	3.17%	-24.07%
PLTH	47 Neutral	C$70.56M	-1.02	-80.81%	―	2.19%	-91.41%
LEEF	46 Neutral	C$58.57M	-0.85	163.84%	―	―	―